Logo
x

Search

Subscribe Now

Sumitomo Pharma

Sumitomo Pharma’s Gemtesa (Vibegron) Secures the US FDA’s Approval to Treat Overactive Bladder (OAB) Symptoms in Men

Sumitomo Pharma’s Gemtesa (Vibegron) Secures the US FDA’s Approval to Treat Overactive Bladder (OAB) Symptoms in Men

  • December 25, 2024
Sumitomo Pharma and Otsuka Failed to Meet its Primary Endpoints of Ulotaront in P-III Trials (DIAMOND 1 & 2) for Schizophrenia

Sumitomo Pharma and Otsuka Failed to Meet its Primary Endpoints of Ulotaront in P-III Trials (DIAMOND 1 & 2) for Schizophrenia

  • August 1, 2023
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.